drugset / Trial / NCT04513860

Cenobamate Expanded Access Program (EAP)

NCT04513860 ↗

Expanded access Approved for marketing SK Life Science, Inc.

Summary

This Cenobamate Expanded Access Program (EAP) is designed to continue providing treatment with Cenobamate (YKP3089) to patients with partial-onset epilepsy that were enrolled in the SK Life Science clinical trial YKP3089C013, YKP3089C017 or YKP3089C021.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Cenobamate Small molecule — —

Indications